Stopped following this story closely, just reviewed the met update. Still a shocker... "median 44%" recovery for critical RE's at pH=1 without resolving in any way to date very high acid consumption due to Ca. Now looking at upstream beneficiation to try and remove the calcium, even though they (and the best minds in this space ) have been working on the met problems since before IPO.
No wonder share price is falling, could not understand how it was defying gravity for so long. Assumed they had some breakthrough extraction tech in the background waiting to be revealed but looks not. Good luck really, happy to see any Aussie success, but betting on tech miracles for flawed projects is a low probability play imo.
AR3 Price at posting:
66.5¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
) have been working on the met problems since before IPO.
(20min delay)